Search
Search
#1. FDA新核准心臟衰竭用藥Vericiguat - 一週全球藥聞
美國食品藥物管理局(FDA)於1月20日批准Merck(默克)和Bayer(拜耳)共同研發的心臟衰竭藥物Vericiguat(VerquvoR),其為口服給藥的水溶性鳥苷酸環化酶(soluble ...
#2. Vericiguat in Patients with Heart Failure and Reduced Ejection ...
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction ...
#3. Vericiguat - StatPearls - NCBI Bookshelf
由 A Vyas 著作 · 2021 — Vericiguat is a medication used to manage and treat heart failure with reduced ejection fraction (HFrEF). It is useful for chronic worsening ...
Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure. ... It is taken by mouth.
#5. A Study of Vericiguat (MK-1242) in Participants With Chronic ...
2021年10月26日 — The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
#6. Verquvo (vericiguat) indications, interactions, adverse effects ...
Medscape - Heart failure dosing for Verquvo (vericiguat), frequency-based adverse effects, comprehensive interactions, contraindications, ...
#7. Verquvo | European Medicines Agency
2021年5月21日 — Vericiguat. International non-proprietary name (INN) or common name. vericiguat. Therapeutic area (MeSH). Heart Failure.
#8. Hemoglobin and Clinical Outcomes in the Vericiguat Global ...
Background: In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred ...
#9. Merck Announces US FDA Approval of VERQUVO® (vericiguat)
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to ...
#10. VERICIGUAT | Drug | BNF content published by NICE
Vericiguat is a stimulator of soluble guanylate cyclase that augments levels of intracellular cyclic guanosine monophosphate, which may improve both ...
#11. Vericiguat Global Study in Subjects With Heart Failure With ...
The VICTORIA trial showed that vericiguat was superior to placebo at improving heart failure outcomes. Description: The goal of the trial was to ...
#12. Vericiguat - an overview | ScienceDirect Topics
Vericiguat is a sGC stimulator that was studied in the SOCRATES-PRESERVED study. In SOCRATES-PRESERVED, patients with HFpEF received vericiguat or placebo.
#13. New Phase III study to investigate expanded use of vericiguat ...
The VICTOR study will explore the efficacy of vericiguat in chronic heart failure patients and reduced ejection fraction of 40 percent or less ...
#14. Vericiguat (Oral Route) Description and Brand Names - Mayo ...
Vericiguat is used to reduce the risk of dying and the need to be hospitalized in patients who have chronic heart failure, who had a recent ...
#15. Mechanism of Action (MOA) of VERQUVO® (vericiguat)
VERQUVO ® (vericiguat) employs a novel MOA for the treatment of HF, resulting in smooth muscle relaxation and vasodilation · This video is either ...
#16. The VITALITY-HFpEF Randomized Clinical Trial - JAMA ...
This randomized trial compares the effect of the oral soluble guanylate cyclase stimulator vericiguat (15 vs 10 mg/d) vs placebo on change ...
#17. vericiguat | Ligand page - IUPHAR/BPS Guide to ...
Comment: Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator [4]. It was initially developed for potential to reduce mortality and ...
#18. Full article: Vericiguat for the treatment of heart failure - Taylor ...
Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that complements the current pharmacotherapy for HF.
#19. Renal function and the effects of vericiguat in patients with ...
Abstract Aims Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients ...
#20. The place of vericiguat in the landscape of treatment for heart ...
The phase 3 VICTORIA trial found that vericiguat is safe and effective in patients with HFrEF and recent HF decompensation. Therefore, adding ...
#21. A Novel Oral Soluble Guanylate Cyclase Stimulator for the ...
ObjectiveTo review the efficacy and safety of vericiguat indicated to reduce the risk of cardiovascular death and heart failure (HF) ...
#22. Verquvo 2.5 mg film-coated tablets - eMC
Vericiguat is a stimulator of soluble guanylate cyclase (sGC). Heart failure is associated with impaired synthesis of nitric oxide (NO) and ...
#23. Vericiguat in the management of heart failure with reduced ...
; for the SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide ...
#24. vericiguat oral: Uses, Side Effects, Interactions ... - WebMD
Find patient medical information for vericiguat oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ...
#25. FDA Approves Vericiguat for High-risk Patients With HF
The US Food and Drug Administration has approved vericiguat (Verquvo), a drug that targets cyclic guanosine monophosphate (cGMP), ...
#26. 搜尋條件428 - 台灣藥物臨床試驗資訊網
試驗計畫標題(名稱), 於低收縮分率心衰竭(HFrEF)受試者,評估口服可溶性鳥苷酸環化酶(sGC)刺激劑Vericiguat之療效與安全性的隨機分配、平行分組、安慰劑對照、雙盲、 ...
#27. Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator For...
In clinical trials, Vericiguat was associated with a reduction in death from cardiovascular causes and first hospitalization in comparison to ...
#28. Bayer, Merck's vericiguat hits endpoint in heart failure phase 3
A phase 3 trial of Bayer and Merck's vericiguat in heart failure patients has.
#29. VERQUVO® (vericiguat) | Official Patient Website
Find information about VERQUVO® (vericiguat) and a coupon offer for eligible, privately insured patients. Talk to your doctor to see if VERQUVO is right for ...
#30. VERQUVO (vericiguat) for the Treatment of Heart Failure, US
VERQUVO ® (vericiguat) is a stimulator of soluble guanylate cyclase (sGC) indicated to reduce the risk of cardiovascular death and heart ...
#31. Vericiguat可改善高危心力衰竭患者预后
Vericiguat 是一种新型口服的可溶性鸟苷酸环化酶激动剂,其在心力衰竭和射血分数降低的患者中疗效尚不清楚。为此,有学者进行了一项临床试验,旨在评价Vericiguat对住院 ...
#32. The Recent FDA Approval of Vericiguat for Heart Failure
... Alexandra Goncharenko, PharmD, BCPS, BCCP, reviews the mechanism of action of vericiguat and considers its place in the treatment landscape.
#33. 台中慈濟藥訊
Vericiguat. 是一種口服可溶性鳥苷酸環化酶促進劑(oral soluble guanylate cyclase stimulator)4,. 此類藥原為肺動脈高壓治療藥物,作用於一氧化氮- 可溶性鳥苷酸環 ...
#34. Vericiguat in heart failure – who benefits the most?
Vericiguat is an oral sGC stimulator enhancing the sensitivity of sGC to endogenous NO and directly stimulating it in a NO-independent manner, ...
#35. VICTORIA trial summary- Vericiguat in Heart Failure - RxFiles
VerICiguaT global study in subjects with heart failure with reduced ejection fraction. SUMMARY. • In VICTORIA, recently decompensated HF-rEF patients (66.9% ...
#36. Dr Derek Chew on the VICTORIA Trial and the Cost ...
The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in ...
#37. Vericiguat-Subjects With Heart Failure With Reduced Ejection ...
Vericiguat belongs to a novel class of oral stimulator of the soluble guanylate cyclase (sGC) enzyme which induces synthesis of a signaling molecule called ...
#38. Vericiguat: MedlinePlus Drug Information
Vericiguat may harm the fetus. If you are sexually active and able to become pregnant, you should not begin taking vericiguat until a pregnancy ...
#39. Vericiguat - Guanylate Cyclase modulator - Selleck Chemicals
Vericiguat (BAY1021189) is a potent, soluble and orally available stimulator of guanylate cyclase. Quality confirmed by NMR & HPLC.
#40. 214377s000lbl.pdf - Accessdata.fda.gov
See full prescribing information for VERQUVO. VERQUVOTM (vericiguat) tablets, for oral use. Initial U.S. Approval: 2021. WARNING: EMBRYO-FETAL TOXICITY. See ...
#41. FDA Approves Vericiguat for Reducing Cardiovascular Death ...
Vericiguat was superior to placebo in reducing the risk of cardiovascular death or heart-failure hospitalization based on a time-to-event ...
#42. FDA Clears Vericiguat to Treat Heart Failure Following…
Vericiguat is a soluble guanylate cyclase (sGC) stimulator, and is the first drug in this class ro be cleared by the FDA for heart failure. The ...
#43. Synthesis of Vericiguat - Thieme Connect
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic. Heart Failure. J. Med. Chem.
#44. VERICIGUAT - Inxight Drugs
Vericiguat, discovered at Bayer, is the first soluble guanylate cyclase (sGC) stimulator. Vericiguat is currently being studied in a Phase III clinical ...
#45. Merck Announces Initiation of Phase 3 Study ... - Yahoo Finance
"The VICTOR study will assess initiating vericiguat earlier in the heart failure journeys of certain patients," said Dr. Javed Butler, the ...
#46. ESC HF 21: Vericiguat in Patients w/ AFib and HF with HFrEF
ESC HF 21 Video: Study on vericiguat for treatment of patients with atrial fibrillation (AF/AFib) and heart failure with reduced ejection ...
#47. vericiguat (Verquvo) - Scottish Medicines Consortium
vericiguat (Verquvo®) is not recommended for use within NHSScotland. Indication under review: Treatment of symptomatic chronic heart failure ...
#48. Benefit assessment according to §35a Social Code Book V
Vericiguat (cardiac failure) - Benefit assessment according to §35a Social ... Extract of dossier assessment: Vericiguat (cardiac failure) ...
#49. Merck Announces Initiation of Phase 3 Study ... - BioSpace
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection ...
#50. New drug could potentially offer better treatment for chronic ...
The VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical trial examined the effects of a ...
#51. Vericiguat Uses, Side Effects & Warnings - Drugs.com
Vericiguat may also be used for purposes not listed in this medication guide. Warnings. You should not use vericiguat if you are also using ...
#52. Vericiguat: Uses, Interactions, Mechanism of Action - DrugBank
Vericiguat is a soluble guanylate cyclase stimulator used to reduce heart failure-related hospitalization and cardiovascular death in ...
#53. 心力衰竭新药!拜耳首创sGC刺激剂Verquvo(vericiguat)在欧盟 ...
2021年07月22日讯/生物谷BIOON/ --拜耳(Bayer)近日宣布,欧盟委员会(EC)已批准Verquvo(vericiguat,2.5mg,5mg,10mg片剂),该药是一种可溶性鸟 ...
#54. CHEBI:142432 - vericiguat - EMBL-EBI
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR ...
#55. Discovery of the Soluble Guanylate Cyclase Stimulator ...
These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for ...
#56. Vericiguat - Side Effects, Interactions, Uses, Dosage, Warnings
Vericiguat is used in certain adults with chronic heart failure, to lower the risk of death or needing to be in the hospital.
#57. Merck Announces US FDA Approval of VERQUVO® (vericiguat)
VERQUVO (vericiguat) 2.5 mg, 5 mg, and 10 mg tablets is being jointly developed with Bayer AG. The VERQUVO label contains a boxed warning that indicates ...
#58. Vericiguat — Study summaries - NERDCAT
Bottom line: In patients with heart failure (HF) with reduced ejection fraction, vericiguat compared with placebo: ...
#59. Vericiguat (Verquvo) - Western Health Advantage
Vericiguat (Verquvo®). Self Administration – Oral. Diagnosis considered for coverage: Chronic Heart Failure - indicated to reduce the risk of cardiovascular ...
#60. Vericiguat (Verquvo) for Heart Failure With Reduced Ejection ...
On January 20, 2021, the FDA approved vericiguat (Verquvo; Merck) for use in adults with symptomatic HF and an ejection fraction less than ...
#61. KEGG DRUG: Vericiguat
D11051 Vericiguat (JAN/USAN/INN) <JP/US> Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 21 Cardiovascular agents
#62. FDA Approves Vericiguat for Use in Patients With Heart Failure
The US Food and Drug Administration (FDA) has approved the cardiovascular drug vericiguat. The drug is a once-daily oral treatment for ...
#63. FDA OKs Vericiguat for Unique HF Population | MedPage Today
FDA approved vericiguat (Verquvo) on Wednesday to lower cardiovascular events in patients with heart failure with reduced ejection fraction ...
#64. No additional effect with sGC stimulator on LVEF and LVESVI ...
Effect of Vericiguat on Left Ventricular Function: The VICTORIA Echocardiographic Sub-Study. HFA Discoveries 2020 webinar presented by Prof.
#65. FDA Approves Vericiguat (Verquvo) for Treatment of Heart ...
The US FDA has approved vericiguat (Verquvo) for reducing the risk of cardiovascular death and heart failure hospitalization following a ...
#66. 2021年第一批FDA批准默沙東/拜耳慢性心衰竭藥
美國時間20日,默沙東(MSD)宣布,其與拜耳(Bayer)共同開發的心衰竭藥物Verquvo(vericiguat)獲美國食品藥品監督管理局(FDA)批准,其為一種口服的水溶性 ...
#67. Verquvo™ (vericiguat) – New drug approval - Professionals ...
January 20, 2021 - Merck announced the FDA approval of Verquvo (vericiguat), to reduce the risk of cardiovascular (CV) death and heart ...
#68. Vericiguat - Clarivate
About vericiguat · Developed by Bayer AG and Merck & Co · Soluble guanylate cyclase stimulator · In the U.S., indicated for treatment of adults with chronic HFrEF ...
#69. Vericiguat meets primary endpoint in worsening chronic heart ...
Vericiguat is an oral, once-daily, direct stimulator of the soluble guanylate cyclase (sGC) enzyme and is the first drug of this class to reach ...
#70. ACC 2020: VICTORIA Trial Shows Vericiguat Improves ...
ACC 2020: VICTORIA Trial Shows Vericiguat Improves Outcomes In High-Risk Heart Failure Patients. Findings suggest vericiguat may be a novel ...
#71. The VICTORIA (Vericiguat Global Study in Subjects With Heart ...
The VICTORIA (Vericiguat. Global Study in Subjects. With Heart Failure With. Reduced Ejection. Fraction) Trial. Paul W. Armstrong, Burkert Pieske, ...
#72. Vericiguat Heart Failure With Reduced Ejection Fraction Study
Abstract Objectives The purpose of this study was to examine the treatment effect of vericiguat in relation to N-terminal pro-B-type natriuretic peptide ...
#73. Verquvo (vericiguat): Basics, Side Effects & Reviews - GoodRx
Verquvo (vericiguat) is used in adults with chronic (long-lasting) heart failure to lower the risk of dying and lessen the need to go to the hospital for ...
#74. Vericiguat Manufacturer1: Merck & Co, Inc. Drug Class1,2,3
reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1675-1683.
#75. Vericiguat的搜索结果-临床试验注册中心
Vericiguat 的临床试验。临床试验注册。 ICH GCP。 ... 搜索临床试验以:Vericiguat. 总计2个结果. NCT01951625 ... Vericiguat 的QT / QTc 间期延长潜力的研究.
#76. Vericiguat well tolerated but not statistically significant in ...
A phase 2 trial of the drug vericiguat did not show a statistically significant reduction of N-terminal pro-B-type natriuretic peptide ...
#77. Side Effects of Verquvo (Vericiguat Tablets), Warnings, Uses
Verquvo (vericiguat) is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) ...
#78. Vericiguat (Verquvo®). HTA ID: 21027 | National Centre for ...
Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a ...
#79. Vericiguat (Verquvo®) - Straight Healthcare
Vericiguat is a soluble guanylate cyclase (sGC) stimulator that is approved to treat heart failure with reduced ejection fraction.
#80. Merck, Bayer flesh out vericiguat heart failure data at ACC
Bayer and Merck & Co have unveiled the data from their phase 3 trial of vericiguat in high-risk heart failure, backing up a top-line message ...
#81. The clinical development of sGC modulators, riociguat and ...
Riociguat and vericiguat are two representatives of modulators of the soluble guanylate cyclase and are able to increase cyclic GMP even in ...
#82. Merck Announces Initiation of Phase 3 Study Evaluating ...
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection ...
#83. ACC House Call: Breaking Down Vericiguat in VICTORIA
#84. Vericiguat reduced a composite of CV death or HF ...
Source Citation Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction.
#85. SOCRATES-REDUCED: Vericiguat effect on NT-proBNP in ...
ORLANDO, Fla. — Vericiguat, a novel soluble guanylate cyclase stimulator, did not significantly influence changes in N-terminal pro-B-type ...
#86. Vericiguat 在射血分数降低的心力衰竭治疗领域中的地位 - X-MOL
The significant morbidity and mortality associated with heart failure with reduced (HFrEF) or preserved ejection fraction (HFpEF) justify ...
#87. VICTORIA results deepen mystery of vericiguat in low-EF ...
Although clinical outcomes improved for patients with high-risk heart failure (HF) who received vericiguat (Merck/Bayer) on top of standard ...
#88. Vericiguat Tablets (Verquvo) | 2021-02-24 | Relias Media
Vericiguat is indicated to lower the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart ...
#89. Vericiguat – Medicines - Specialist Pharmacy Service
Jul 20 · FDA has granted a priority review for vericiguat. PDUFA date has been agreed for January 2021 [10]. Jun 20 · Bayer announces the ...
#90. Vericiguat (Verquvo) for Heart Failure | The Medical Letter, Inc.
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization ...
#91. Merck and Bayer's heart drug vericiguat meets ... - Reuters
Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary ...
#92. Vericiguat (BAY1021189) | sCG Stimulator | MedChemExpress
Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator. - Mechanism of Action & Protocol.
#93. FDA Approves Vericiguat for Chronic Heart Failure - HCPLive
The US Food and Drug Administration (FDA) has approved vericiguat (VERQUVO) for the reduced risk of cardiovascular death and heart failure ...
#94. NEJM:Vericiguat可降低高危心衰患者不良预后风险 - 梅斯医学
Vericiguat 是一种新型口服可溶性鸟苷酸环化酶激动剂,近日研究人员考察了其对住院或接受静脉利尿剂的心力衰竭和射血分数降低患者的治疗效果。
#95. Cardiovascular and noncardiovascular effects of vericiguat ...
Cardiovascular and noncardiovascular effects of vericiguat. Figure legend: NO, nitroxigen oxide; sGC, soluble guanylate cyclase; GTP, guanosine triphosphate ...
vericiguat 在 ACC House Call: Breaking Down Vericiguat in VICTORIA 的必吃
... <看更多>